The effect of recombinant human GH replacement therapy on lipoprotein(a) and other lipid parameters in adults with acquired GH deficiency: Results of a double-blind and placebo-controlled trial

European Journal of Endocrinology

Volumn 137, Issue 5, 1997, Pages 459-466

  Nolte, Wilhelm ^a   Rädisch, Carsten ^a   Armstrong, Victor W ^a   Hüfner, Michael ^a   Von Zur Mühlen, Alexander ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RECOMBINANT GROWTH HORMONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG SAFETY; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPOPROTEINEMIA; LIPID METABOLISM; MALE; MULTICENTER STUDY; PHENOTYPE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 1842291603     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1370459     Document Type: Article

References (46)

1. Rosén T, Johannsson G, Johansson JO & Bengtsson BA. Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment. Hormone Research 1995 43 93-99.
2. Powrie J, Weissberger A & Sönksen P. Growth hormone replacement therapy for growth hormone-deficient adults. Drugs 1995 49 656-663.
3. Russell-Jones DL, Weissberger AJ, Bowes SB, Kelly JM, Thomason M, Umpleby AM, Jones RH & Sönksen PH. Protein metabolism in growth hormone deficiency, and effects of growth hormone replacement therapy. Acta Endocrinologica 1993 128 (Suppl 2) 44-47.
4. Bengtsson BA, Eden S, Loon L, Kvist H, Stokland A, Lindstedt G, Bosaeus I, Tolli J, Sjostrom L & Isaksson OG. Treatment of adults with growth hormone deficiency with recombinant human growth hormone. Journal of Clinical Endocrinology and Metabolism 1993 76 309-317.
5. Beshyah SA, Freemantle C, Shahi M, Anyaoku V, Merson S, Lynch S, Skinner E, Sharp P, Foale R & Johnston DG. Replacement treatment with biosynthetic human growth hormone in growth hormone-deficient hypopituitary adults. Clinical Endocrinology 1995 42 73-84.
6. Utermann G. The mysteries of Lipoprotein (a). Science 1989 246 904-910.
7. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Mänttäri M, Manninen V & Huttunen JK. Lipoprotein(a) and coronary heart disease risk. A nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991 89 59-67.
8. Ridker PM, Hennekens CH & Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. Journal of the American Medical Association 1993 270 2195-2199.
9. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B & Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. British Medical Journal 1990 301 1248-1251.
10. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H & Seidel D. Lipoprotein Lp(a) as a predictor of myocardial infarction in comparison to fibrinogen. LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). European Journal of Clinical Investigation 1994 24 444-453.
11. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, Lippel K & Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men. Journal of the American Medical Association 1994 271 999-1003.
12. Olivecrona H, Ericsson S, Berglund L & Angelin B. Increased concentrations of serum Lp(a) in response to growth hormone treatment. British Medical Journal 1993 306 1726-1727.
13. Oscarsson J, Ottosson M, Wiklund O, Marin P, Vikmann-Adolfsson K, Björntorp P & Eden S. Low dose continuously infused growth hormone results in increased Lp(a) and decreased LDL-cholesterol concentrations in middle-aged men. Clinical Endocrinology 1994 41 109-116.
14. Hansen PS, Kassem M, Brixen K, Klausen IC, Mosekilde L & Faergeman O. Effect of short-term treatment with recombinant human growth hormone on lipids and lipoproteins in women and men without growth hormone disturbances. Metabolism 1995 6 725-729.
15. Olivecrona H, Johansson AG, Lindh E, Ljunghall S, Berglund L & Angelin B. Hormonal regulation of serum Lp(a) levels. Contrasting effects of growth hormone and IGF 1. Arteriosclerosis Thrombosis and Vascular Biology 1995 15 847-849.
16. Johannsson G, Oscarsson J, Rosén T, Wiklund O, Olsson G, Wilhelmsen L & Bengtsson BA. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and Apo(a) and ApoE phenotypes. Arteriosclerosis Thrombosis and Vascular Biology 1995 15 2142-2150.
17. Garry P, Collins P & Devlin JG. An open 36-month study of lipid changes with growth hormone in adults: lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency. European Journal of Endocrinology 1996 134 61-66.
18. Weaver JU, Monson JP, Noonan K, John WG, Edwards A, Evans KA & Cunningham J. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity and cardiovascular risk factors in hypopituitary adults. Journal of Clinical Endocrinology and Metabolism 1995 80 153-159.
19. Eden S, Wiklund O, Oscarsson J, Rosén T & Bengtsson BA. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arteriosclerosis and Thrombosis 1993 13 296-301.
20. Russel-Jones DL, Watts GF, Weissberger A, Naoumova R, Myers J, Thompson GR & Sönksen PH. The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clinical Endocrinology 1994 41 345-350.
21. Helmhold M, Bigge J, Muche R, Mainoo J, Thiery J, Seidel D & Armstrong VW. Contribution of the apo(a) phenotype to plasma Lp(a) concentrations shows considerable ethnic variation. Journal of Lipid Research 1991 32 1919-1928.
22. Von Ahsen N, Helmhold M, Eisenhauer T, Armstrong VW & Oellerich M. Decrease in lipoprotein(a) after renal transplantation is related to the glucocorticoid dose. European Journal of Clinical Investigation 1996 26 668-675.
23. Kannel WB. Cholesterol and risk of coronary heart disease and mortality in men. Clinical Chemistry 1988 34 B53-B59.
24. Stampfer MJ, Sachs FM, Salvini S, Willet WC & Hennekens CH. A prospective study of cholesterol, apolipoproteins and the risk of myocardial infarction. New England Journal of Medicine 1991 325 373-381.
25. Merimee TJ, Hollander W & Fineberg E. Studies of hyperlipidemia in the hGH-deficient state. Metabolism 1972 21 1053-1061.
26. De Boer H, Blok GJ, Voerman HJ, Phillips M & Schouten JA. Serum lipid levels in growth hormone-deficient men. Metabolism 1994 43 199-203.
27. Nikkilä EA & Pelkonen R. Serum lipids in acromegaly. Metabolism 1975 24 829-838.
28. Rosén T & Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990 336 285-288.
29. Rosén T, Edén S, Larson G, Wilhelmsen L & Bengtsson BA. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinologica 1993 129 195-200.
30. Wüster C, Slenczka E & Ziegler R, Erhöhte Prävalenz von Osteoporose und Arteriosklerose bei konventionell substituierter Hypophysenvorderlappeninsuffizienz: Bedarf einer zusätzlichen Wachstumshormonsubstitution? Klinische Wochenschrift 1991 69 769-773.
31. Markussis V, Beshyah SA, Fisher C, Sharp P, Nicolaides AN & Johnston DG. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 1992 340 1188-1192.
32. Nolte W, Gonska BD, Siegel EG & Hüfner M. Gibt es eine akromegale Kardiomyopathie? Aktnelle Endokrinologie und Stoffwechsel 1992 13 29-34.
33. Salomon F, Cuneo RC, Hesp R & Sönksen PH. The effect of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. New England Journal of Medicine 1989 321 1797-1803.
34. Whitehead HM, Boreham C, McIlrath EM, Sheridan B, Kennedy L, Atkinson AB & Hadden DR. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clinical Endocrinology 1992 36 45-52.
35. Cuneo RC, Salomon F, Watts GF, Hesp R & Sönksen PH. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 1993 12 1519-1523.
36. O'Halloran D J, Wieringa G, Tsatsoulis A & Shalet SM. Serum lipoprotein(a) levels increase after recombinant human growth hormone (GH) in adults with isolated GH deficiency. Journal of Endocrinology 1994 130 (Suppl) Abstract P171.
37. Stiegler C & Leb G. One year of replacement therapy in adults with growth hormone deficiency. Endocrinology and Metabolism 1994 1 (Suppl A) 37-42.
38. Rosén T, Johannsson G, Hallgren P, Caidahl K, Bosaeus I & Bengtsson BA. Beneficial effects of 12 months replacement therapy with recombinant human growth hormone to growth hormone deficient adults. Endocrinology and Metabolism 1994 1 55-56.
39. Hintz RL, Rosenfeld RG, Wilson DM, Bennett A, Finno J, McClellan B & Swift R. Biosynthetic methionyl human growth hormone is biologically active in adult man. Lancet 1982 i 1276-1281.
40. Møller A, Rasmussen LM, Thuesen L & Christiansen JS. Impact of human growth hormone on plasma lipoprotein concentrations. Hormone and Metabolic Research 1989 21 207-209.
41. Blackett PR, Weech PK, McConathy WJ & Fesmire JD. Growth hormone in the regulation of hyperlipidemia. Metabolism 1982 31 117-120.
42. Winter R & Green OC. Effect of thyroxine and growth hormone on the hypercholesterinemia of growth hormone deficiency. Metabolism 1983 33 54-57.
43. Asayama K, Amemiya S, Kusano S & Kato K. Growth-hormone-induced changes in postheparin plasma lipoprotein lipase and hepatic triglyceride lipase activities. Metabolism 1984 33 129-131.
44. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H & Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis 1986 62 249-257.
45. Durrington PN, Ishola M, Hunt L, Arrol S & Bhatnagar D. Apolipoproteins(a), AI and B and parental history in men with early onset ischaemic heart disease. Lancet 1988 i 1070-1073.
46. Simons L, Friedlander Y, Simons J & McCallum J. Lipoprotein(a) is not associated with coronary heart disease in the elderly: cross-sectional data from the Dubbo study. Atherosclerosis 1993 99 87-95.